The DOI matches its Crossref record.
Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers
Abstract
The effects of fluoxetine, a relatively selective long-acting serotonin uptake inhibitor, on the consumption of alcoholic and nonalcoholic drinks, cigarette smoking, and body weight were assessed in 29 men who were early stage problem drinkers. After a 2-week baseline, subjects were randomly assigned to receive 40 mg/day fluoxetine (n = 8), 60 mg/day fluoxetine (n = 11), or placebo (n = 10) for 4 weeks. Fluoxetine 60 mg/day decreased mean daily alcoholic drinks from (X +/- SEM) 8.3 +/- 0.7 during baseline to 6.9 +/- 0.7 and decreased total drinks per 14 days from 115.8 +/- 9.3 to 96.5 +/- 9.5 (p less than 0.01; 17.3% decrease from baseline), with no significant increase in days of abstinence. Neither 40 mg/day fluoxetine nor placebo had effects on intake of alcohol. Fluoxetine 60 mg/day decreased total and mean daily alcoholic drinks compared with 40 mg/day fluoxetine (ANCOVA, both p less than 0.02), but neither dose of fluoxetine was different from placebo. Compared with placebo, both 40 mg/day fluoxetine and 60 mg/day fluoxetine no differences were detected between treatment groups, 60 mg/day fluoxetine increased mean daily nonalcoholic beverages from baseline (5.0 +/- 0.4 to 5.6 +/- 0.3, p less than 0.01) and increased daily cigarettes smoked (from 25.1 +/- 4.6 to 26.9 +/- 4.5, p less than 0.05), whereas no significant changes from baseline were observed with 40 mg/day fluoxetine or placebo.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wong, D. T., Bymaster, F. P., & Engleman, E. A. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00209-o · Cited by 647
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
The neurobiology of drug addiction
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.3.482 · Cited by 562
Neurocircuitry Targets in Ethanol Reward and Dependence
Koob, G. F., Roberts, A. J., Schulteis, G., Parsons, L. H., Heyser, C. J., Hyyti??, P., Merlo-Pich, E., & Weiss, F. (1998) · Alcoholism: Clinical & Experimental Research · doi:10.1097/00000374-199802000-00001 · Cited by 560
Relapse Prevention by Acamprosate: Results From a Placebo-Controlled Study on Alcohol Dependence
Sass, H. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830080023006 · Cited by 479
Weiss, F., Parsons, L. H., Schulteis, G., Hyytiä, P., Lorang, M. T., Bloom, F. E., & Koob, G. F. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-10-03474.1996 · Cited by 457
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Fluoxetine in Depressed Alcoholics: A Double-blind, Placebo-Controlled Trial
Cornelius, J. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200024004 · Cited by 357
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 348
Serotonin and alcohol intake, abuse, and dependence: Clinical evidence
LeMarquand, D., Pihl, R. O., & Benkelfat, C. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90630-0 · Cited by 335
"Loss of control" in alcoholism and drug addiction: A neuroscientific interpretation.
Lyvers, M. (2000) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.8.2.225 · Cited by 311
Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.3.391 · Cited by 289
Review of sertraline and its clinical applications in psychiatric disorders
McRae, A. L., & Brady, K. T. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.5.883 · Cited by 287
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.1.83 · Cited by 269
Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264
Mason, B. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530340025025 · Cited by 257
Buspirone Treatment of Anxious Alcoholics: A Placebo-Controlled Trial
Kranzler, H. R. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950090052008 · Cited by 248
Antidepressants for smoking cessation
Hajizadeh, A., Howes, S., Theodoulou, A., Klemperer, E., Hartmann-Boyce, J., Livingstone-Banks, J., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub6 · Cited by 84
Disruptive Behavior Disorders and Substance Use Disorders in Adolescents
Bukstein, O. G. (2000) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2000.10400213 · Cited by 50
Effect of Nonnicotine Pharmacotherapy on Smoking Behavior
Kotlyar, M., Golding, M., Hatsukami, D. K., & Jamerson, B. D. (2001) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.20.1530.34477 · Cited by 32
Substance‐Related Disorders: Alcohol‐Related Disorders
Babor, T. F., Hernandez‐Avila, C. A., & Ungemack, J. A. (2015) · Psychiatry · doi:10.1002/9781118753378.ch72 · Cited by 8
Metadata
- Authors
- Naranjo, C. A., Kadlec, K. E., Sanhueza, P., Woodley-Remus, D., & Sellers, E. M.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1990-04
- Volume
- 47
- Issue
- 4
- Pages
- 490-498
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2012412792
- Cited by
- 224
- References
- 0
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.